The appointment is effective as of May 16, 2024. In her new role, Annapurna will lead the Company in India, ensuring patient access to its highly innovative medicines and vaccines, and advancing valuable collaborations to contribute to the growing domestic healthcare and pharmaceutical market. (TSE:4502/NYSE:TAK) Takeda Biopharmaceuticals